Toxic shock syndrome toxin-1-mediated toxicity inhibited by neutralizing antibodies late in the course of continual in vivo and in vitro exposure.

Leaky RAG Deficiency in Adult Patients with Impaired Antibody Production against Bacterial Polysaccharide Antigens. PLoS One (2015) 0.78

Genotypic and phenotypic analysis of clinical isolates of Staphylococcus aureus revealed production patterns and hemolytic potentials unlinked to gene profiles and source. BMC Microbiol (2016) 0.77

Human scFvs That Counteract Bioactivities of Staphylococcus aureus TSST-1. Toxins (Basel) (2017) 0.75

Enterotoxins: Microbial Proteins and Host Cell Dysregulation. Toxins (Basel) (2016) 0.75

The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med (2003) 32.30

The pathophysiology and treatment of sepsis. N Engl J Med (2003) 21.67

Sepsis in European intensive care units: results of the SOAP study. Crit Care Med (2006) 11.78

Regulation of lymphokine messenger RNA stability by a surface-mediated T cell activation pathway. Science (1989) 7.78

Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med (1996) 5.25

Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA (1994) 5.24

Novel strategies for the treatment of sepsis. Nat Med (2003) 5.14

A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group. N Engl J Med (1996) 4.86

The enigma of sepsis. J Clin Invest (2003) 4.32

Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med (2002) 2.47

Control of gene expression during T cell activation: alternate regulation of mRNA transcription and mRNA stability. BMC Genomics (2005) 2.18

Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med (2001) 1.96

Cytokines in sepsis: potent immunoregulators and potential therapeutic targets--an updated view. Mediators Inflamm (2013) 1.54

Microarray-based analyses of mRNA decay in the regulation of mammalian gene expression. Brief Funct Genomic Proteomic (2004) 1.44

Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun (1993) 1.33

Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 1.27

Inhibition of bacterial superantigens by peptides and antibodies. Infect Immun (2001) 1.24

Superantigens are critical for Staphylococcus aureus Infective endocarditis, sepsis, and acute kidney injury. MBio (2013) 1.19

Vaccination with nontoxic mutant toxic shock syndrome toxin 1 protects against Staphylococcus aureus infection. J Infect Dis (2003) 1.15

Rapid transit in the immune cells: the role of mRNA turnover regulation. J Leukoc Biol (2007) 1.14

Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun (2002) 1.10

Cytolysins, superantigens, and pneumonia due to community-associated methicillin-resistant Staphylococcus aureus. J Infect Dis (2009) 1.08

Human antibodies to bacterial superantigens and their ability to inhibit T-cell activation and lethality. Antimicrob Agents Chemother (2001) 1.05

Control of cytokine mRNA expression by RNA-binding proteins and microRNAs. J Dent Res (2012) 1.05

Immunity to Staphylococcus aureus secreted proteins protects rabbits from serious illnesses. Vaccine (2012) 1.04

Update on staphylococcal superantigen-induced signaling pathways and therapeutic interventions. Toxins (Basel) (2013) 1.03

Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B. PLoS One (2010) 1.03

A novel approach to generate a recombinant toxoid vaccine against Clostridium difficile. Microbiology (2013) 1.02

Bench-to-bedside review: Immunoglobulin therapy for sepsis - biological plausibility from a critical care perspective. Crit Care (2012) 1.00

Vaccination against Staphylococcus aureus pneumonia. J Infect Dis (2013) 0.97

Methicillin-resistant staphylococcal infections: an important consideration for orthopedic surgeons. Orthopedics (2004) 0.96

Biological activity of toxic shock syndrome toxin 1 and a site-directed mutant, H135A, in a lipopolysaccharide-potentiated mouse lethality model. Infect Immun (1995) 0.96

Dexamethasone attenuates staphylococcal enterotoxin B-induced hypothermic response and protects mice from superantigen-induced toxic shock. Antimicrob Agents Chemother (2006) 0.94

Pirfenidone blocks the in vitro and in vivo effects of staphylococcal enterotoxin B. Infect Immun (2002) 0.87

Future perspectives on regulating pro-and anti-inflammatory responses in sepsis. Contrib Microbiol (2011) 0.87

Differential kinetics of antigen dependency of CD4+ and CD8+ T cells. J Immunol (2014) 0.87

Therapeutic down-modulators of staphylococcal superantigen-induced inflammation and toxic shock. Toxins (Basel) (2010) 0.85

Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates for TSST-1-induced toxic shock syndrome. Vaccine (2002) 0.82

Intravitreally injected human immunoglobulin attenuates the effects of Staphylococcus aureus culture supernatant in a rabbit model of toxin-mediated endophthalmitis. Arch Ophthalmol (2004) 0.81

Intranasal rapamycin rescues mice from staphylococcal enterotoxin B-induced shock. Toxins (Basel) (2012) 0.81

Analysis of the early response to TSST-1 reveals Vbeta-unrestricted extravasation, compartmentalization of the response, and unresponsiveness but not anergy to TSST-1. J Leukoc Biol (2008) 0.81

Clostridium perfringens epsilon toxin mutant Y30A-Y196A as a recombinant vaccine candidate against enterotoxemia. Vaccine (2014) 0.80

Staphylococcal superantigen (TSST-1) mutant analysis reveals that t cell activation is required for biological effects in the rabbit including the cytokine storm. Toxins (Basel) (2010) 0.80